Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer

Fig. 3

ROR1/CD3 TCE induced T cell activation in a ROR1-dependent manner. (A, B) The activation of CD4+, CD8+ T cells were determined by flow cytometry via analyzing the activation marker CD25 and CD69. (C, D) The proliferation of CD4+ and CD8+ T cells was measured after co-cultured with a serially diluted ROR1/CD3 antibody for 96 h. The experiment was performed with three tecnological replicates, and validated by another PBMC donor

Back to article page